Projected spending for brand-name drugs in English primary care given US prices: a cross-sectional study | Zendy

Michael Liu | Zendy; Brian MacKenna | Zendy; William B. Feldman | Zendy; Alex J Walker | Zendy; Jerry Avorn | Zendy; Aaron S. Kesselheim | Zendy; Ben Goldacre | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Projected spending for brand-name drugs in English primary care given US prices: a cross-sectional study

Author(s) -

Michael Liu,

Brian MacKenna,

William B. Feldman,

Alex J Walker,

Jerry Avorn,

Aaron S. Kesselheim,

Ben Goldacre

Publication year - 2020

Publication title -

journal of the royal society of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.38

H-Index - 81

eISSN - 1758-1095

pISSN - 0141-0768

DOI - 10.1177/0141076820918238

Subject(s) - medicine , medical prescription , new england , cohort , primary care , health survey for england , medicare part d , health spending , family medicine , prescription drug , health services , population , political science , environmental health , nursing , law , politics

To estimate additional spending if NHS England paid the same prices as US Medicare Part D for the 50 single-source brand-name drugs with the highest expenditure in English primary care in 2018.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research